Rapid and Innovative Technology Transfer Activities to Enable ACTT Trial to Test Remdesivir as a Treatment for COVID-19

2021 FLC Impact Award – National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases

December 2019



Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first identified as the cause of a respiratory illness designated as coronavirus disease 2019, or COVID-19

Jan-Feb 2020

NIAID started planning the ACTT trial.
The NIAID Technology Transfer and Intellectual Property Office (TTIPO) supported the Division of Microbiology and Infectious Diseases (DMID) to negotiate a Clinical Trial Agreement (CTA) with Gilead to obtain remdesivir to test under ACTT

February 21, 2020

The NIAID Sponsored ACTT Trial is activated – it was the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

March 2020

The WHO declares that the COVID-19 outbreak is a pandemic

Feb- March 2020

Letters of Agreement were put in place to enable the clinical trials at various sites globally

NIH's Response to COVID-19
COVID19.nih.gov

May 1, 2020

Shortly after the trial results were published, FDA granted an Emergency Use Authorization (EUA) for remdesivir to treat hospitalized patients with severe COVID-19

October 22, 2020

FDA grants approval for remdesivir to treat hospitalized COVID-19 patients